Polyclonal Antibodies Market - Top Companies and Manufacturers

  • Report ID: 5659
  • Published Date: Apr 29, 2024
  • Report Format: PDF, PPT

Companies Dominating the Polyclonal Antibodies Landscape

    • Abcam plc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Bio-Rad Laboratories, Inc.
    • GenScript Biotech Corporation
    • BioLegend, Inc.
    • Cell Signaling Technology, Inc.
    • Rockland Immunochemicals Inc.
    • Agilent Technologies, Inc.
    • Fitzgerald Industries International

Browse Key Market Insights with Data Illustration:

In the News

  • Xenothera- announced their recent evidence which supports the importance of using glycol-humanized polyclonal antibody XAV-19 for treating patients during the initial viral phase of the disease.
  • Merck and Kelun-Biotech- announced the seven different exploratory preclinical antibody-drug conjugates, especially for cancer treatment.

Author Credits:  Radhika Pawar


  • Report ID: 5659
  • Published Date: Apr 29, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of barge transportation was over USD 10 Billion.

The market size for the polyclonal antibodies market is projected to cross USD 26 Billion by the end of 2036 expanding at a CAGR of 8% during the forecast period i.e., between 2024-2036.

The major players in the market are Thermo Fisher Scientific Inc., Merck KGaA, Bio-Rad Laboratories, Inc., GenScript Biotech Corporation, BioLegend, Inc., Cell Signaling Technology, Inc., Rockland Immunochemicals Inc., Agilent Technologies, Inc., Fitzgerald Industries International, Fujifilm Corporation, Wako Pure Chemical Industries, Ltd., Cosmo Bio Co., Ltd., MBL International Corporation, Abnova Corporation., and others.

In terms of type, the human source segment is anticipated to account for the largest market share of 54% during 2024-2036.

The Asia Pacific polyclonal antibodies sector is poised to hold the highest share of 47% by 2036.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample